Cosmo Pharmaceuticals (OTCMKTS:CMOPF) Sees Large Decline in Short Interest

Cosmo Pharmaceuticals (OTCMKTS:CMOPF) was the target of a significant decline in short interest in May. As of May 15th, there was short interest totaling 14,592 shares, a decline of 37.2% from the April 30th total of 23,228 shares. Based on an average trading volume of 597 shares, the short-interest ratio is presently 24.4 days.

Cosmo Pharmaceuticals Stock Performance

OTCMKTS:CMOPF opened at C$93.62 on Friday. The company has a fifty day simple moving average of C$106.34 and a two-hundred day simple moving average of C$120.75. Cosmo Pharmaceuticals has a 52 week low of C$75.00 and a 52 week high of C$169.90.

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy.